EDITAS MEDICINE, INC. (EDIT) Free cash flow
- Free cash flow · 12 months (USD): Value $-120.55M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -256.46%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-120.55M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-119.86M − $691.00K ≈ $-120.55M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -256.46% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-120.55M ÷ $47.01M × 100 ≈ -256.46% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-119.86M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.62× | Operating cash flow / net income. Period ending 2026-06-30. $-119.86M ÷ $-73.95M ≈ 1.62× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -119.86M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 691.00K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -120.55M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 47.01M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -73.95M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-120.55M | (m) | $-119.86M | $691.00K | (m) | $47.01M | (m) | $-73.95M | (m) | (m) | -256.46% | 1.62× |
| 2026-03-31 | $-141.09M | (m) | $-140.50M | $585.00K | (m) | $38.69M | (m) | $-108.95M | (m) | (m) | -364.63% | 1.29× |
| 2025-12-31 | $-165.85M | (m) | $-165.24M | $607.00K | (m) | $40.52M | (m) | $-160.06M | (m) | (m) | -409.30% | 1.03× |
| 2025-09-30 | $-180.70M | (m) | $-179.62M | $1.09M | (m) | $46.38M | (m) | $-199.84M | (m) | (m) | -389.59% | 0.90× |
| 2025-06-30 | $-204.94M | (m) | $-201.36M | $3.58M | (m) | $38.90M | (m) | $-236.86M | (m) | (m) | -526.81% | 0.85× |
| 2025-03-31 | $-215.28M | (m) | $-208.21M | $7.07M | (m) | $35.84M | (m) | $-251.23M | (m) | (m) | -600.72% | 0.83× |
| 2024-12-31 | $-219.11M | (m) | $-210.28M | $8.83M | (m) | $32.31M | (m) | $-237.09M | (m) | (m) | -678.07% | 0.89× |
| 2024-09-30 | $-191.35M | (m) | $-181.76M | $9.59M | (m) | $61.76M | (m) | $-210.57M | (m) | (m) | -309.84% | 0.86× |
| 2024-06-30 | $-171.54M | (m) | $-164.63M | $6.91M | (m) | $67.03M | (m) | $-193.45M | (m) | (m) | -255.91% | 0.85× |
| 2024-03-31 | $-151.03M | (m) | $-146.28M | $4.75M | (m) | $69.41M | (m) | $-166.13M | (m) | (m) | -217.60% | 0.88× |
| 2023-12-31 | $-136.90M | (m) | $-132.18M | $4.72M | (m) | $78.12M | (m) | $-153.22M | (m) | (m) | -175.23% | 0.86× |
| 2023-09-30 | $-156.25M | (m) | $-152.21M | $4.04M | (m) | $24.61M | (m) | $-195.08M | (m) | (m) | -634.89% | 0.78× |
| 2023-06-30 | $-169.17M | (m) | $-164.76M | $4.41M | (m) | $19.32M | (m) | $-205.79M | (m) | (m) | -875.79% | 0.80× |
| 2023-03-31 | $-167.60M | (m) | $-163.89M | $3.71M | (m) | $22.79M | (m) | $-218.95M | (m) | (m) | -735.35% | 0.75× |
| 2022-12-31 | $-181.47M | (m) | $-177.35M | $4.12M | (m) | $19.71M | (m) | $-220.43M | (m) | (m) | -920.59% | 0.80× |
| 2022-09-30 | $-176.00M | (m) | $-169.66M | $6.34M | (m) | $25.64M | (m) | $-201.13M | (m) | (m) | -686.28% | 0.84× |
| 2022-06-30 | $-170.51M | (m) | $-162.44M | $8.07M | (m) | $31.80M | (m) | $-184.49M | (m) | (m) | -536.19% | 0.88× |
| 2022-03-31 | $-173.69M | (m) | $-163.55M | $10.14M | (m) | $25.82M | (m) | $-186.29M | (m) | (m) | -672.81% | 0.88× |
| 2021-12-31 | $-171.78M | (m) | $-163.80M | $7.98M | (m) | $25.54M | (m) | $-192.50M | (m) | (m) | -672.49% | 0.85× |
| 2021-09-30 | $-175.83M | (m) | $-169.32M | $6.51M | (m) | $24.49M | (m) | $-213.56M | (m) | (m) | -717.85% | 0.79× |
| 2021-06-30 | $-189.29M | (m) | $-183.34M | $5.96M | (m) | $81.14M | (m) | $-166.66M | (m) | (m) | -233.30% | 1.10× |
| 2021-03-31 | $-180.33M | (m) | $-175.24M | $5.09M | (m) | $91.51M | (m) | $-134.98M | (m) | (m) | -197.06% | 1.30× |
| 2020-12-31 | $-187.00M | (m) | $-179.84M | $7.16M | (m) | $90.73M | (m) | $-115.98M | (m) | (m) | -206.11% | 1.55× |
| 2020-09-30 | $-106.20M | (m) | $-98.72M | $7.48M | (m) | $91.60M | (m) | $-91.25M | (m) | (m) | -115.94% | 1.08× |
| 2020-06-30 | $-78.73M | (m) | $-70.80M | $7.93M | (m) | $32.60M | (m) | $-132.01M | (m) | (m) | -241.48% | 0.54× |
| 2020-03-31 | $-73.35M | (m) | $-65.75M | $7.60M | (m) | $24.18M | (m) | $-142.22M | (m) | (m) | -303.30% | 0.46× |
| 2019-12-31 | $-46.84M | (m) | $-40.67M | $6.17M | (m) | $20.53M | (m) | $-133.75M | (m) | (m) | -228.12% | 0.30× |
| 2019-09-30 | $-86.26M | (m) | $-80.37M | $5.89M | (m) | $14.37M | (m) | $-121.03M | (m) | (m) | -600.42% | 0.66× |
| 2019-06-30 | $-65.91M | (m) | $-61.32M | $4.58M | (m) | $25.04M | (m) | $-103.33M | (m) | (m) | -263.24% | 0.59× |
| 2019-03-31 | $-56.71M | (m) | $-52.25M | $4.46M | (m) | $30.08M | (m) | $-108.26M | (m) | (m) | -188.54% | 0.48× |
| 2018-12-31 | $-50.46M | (m) | $-45.71M | $4.75M | (m) | $31.94M | (m) | $-109.95M | (m) | (m) | -158.00% | 0.42× |
| 2018-09-30 | $-75.73M | (m) | $-72.10M | $3.63M | (m) | (m) | (m) | $-121.09M | (m) | (m) | (m) | 0.60× |
| 2018-06-30 | $-95.68M | (m) | $-92.24M | $3.44M | (m) | (m) | (m) | $-132.45M | (m) | (m) | (m) | 0.70× |
| 2018-03-31 | $-104.08M | (m) | $-101.67M | $2.41M | (m) | (m) | (m) | $-120.17M | (m) | (m) | (m) | 0.85× |
| 2017-12-31 | $-11.48M | (m) | $-9.42M | $2.06M | (m) | (m) | (m) | $-120.32M | (m) | (m) | (m) | 0.08× |
| 2017-09-30 | $-151.00K | (m) | $2.29M | $2.45M | (m) | (m) | (m) | $-123.51M | (m) | (m) | (m) | -0.02× |
| 2017-06-30 | $10.82M | (m) | $13.23M | $2.41M | (m) | (m) | (m) | $-117.93M | (m) | (m) | (m) | -0.11× |
| 2017-03-31 | $26.29M | (m) | $29.49M | $3.21M | (m) | (m) | (m) | $-110.53M | (m) | (m) | (m) | -0.27× |
| 2016-12-31 | $-53.42M | (m) | $-49.93M | $3.49M | (m) | (m) | (m) | $-97.18M | (m) | (m) | (m) | 0.51× |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-6.83M | (m) | $-5.40M | $1.43M | (m) | (m) | (m) | $-72.90M | (m) | (m) | (m) | 0.07× |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $-9.87M | (m) | $-8.65M | $1.22M | (m) | (m) | (m) | $-13.69M | (m) | (m) | (m) | 0.63× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |